Search

ECDC, after conducting rapid risk assessments, has concluded that the risk of importation of infectious diseases from North Africa to the EU is  considered to be low. From a public health perspective, the most urgent concern is related to the poor living conditions of the migrants, such as overcrowding and poor sanitation.

In January 2008, a panel of ECDC experts produced the Guidance for the introduction of HPV vaccines in EU countries. Since then, the European Union has come a long way: most countries have implemented national vaccination programmes for adolescent girls and a significant number have also introduced catch-up programmes for young women.

The Vaccine Preventable Diseases programme of ECDC has set up a working group to provide guidance to the European Union Member States on the potential introduction of varicella vaccination.

This guidance report lays down the scientific basis for the potential introduction of human papillomavirus (HPV) vaccines in order to help EU Member States to make policy choices

​Early in 2015, a shortage of acellular pertussis-containing vaccines was brought to the attention of ECDC. This risk assessment provides a detailed list of mitigation options available to Member States.

This paper identifies and describes population groups at increased risk for severe outcomes of influenza (“risk groups”) and advocates vaccination for two major groups, namely a) persons in the older age group, usually 65 years and older; and b) persons with chronic medical conditions.

This Rapid Risk Assessment focuses on acellular pertussis-containing combination vaccines used in national vaccination programmes in the EU/EEA Member States.

Antiviral drugs are an important addition to the public health arsenal against influenza. This interim guidance discusses the options for their effective use, especially during a pandemic.

This interim guidance outlines the possible strategies that countries may wish to adopt in the deployment of a pandemic-specific vaccine, considering the two objectives of vaccination: protecting those at greatest risk of severe disease and maintaining essential services.

The final expert opinion on rotavirus vaccination in infancy aims to provide EU/EEA Member States with information to support the decision-making process on the possible introduction of rotavirus vaccination in infancy.